Trial Profile
A Phase 2 Study of OSI-906 in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 02 Dec 2019 Results assessing efficacy of linsitinib in patients with Gastrointestinal Stromal Tumors published in the Clinical Cancer Research
- 10 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 09 Jul 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.